Spiriva Respimat (Tiotropium Bromide) Patent Expiration, LOE Window & CMS Spending

Spiriva Respimat (Tiotropium Bromide) by Boehringer Ingelheim: FDA Orange Book LOE 2031-04-16, 1 AB generics, $1.13B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN021936 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-04-16
Orange Book Patents (*PED Extensions)4 patents (4 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$1.13B
2024 Medicare Part D Spend$877.2M
2024 Medicaid Spend$254.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.